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Abstract
Background
There is scant data regarding disease presentation and treatment response among black men
living in Africa. In this study we evaluate disease presentation and early clinical outcomes
among Ghanaian men with prostate cancer treated with external beam radiotherapy (EBRT).

Methods
A total of 379 men with prostate cancer were referred to the National Center for
Radiotherapy, Ghana from 2003 to 2009. Data were collected regarding patient-and tumorrelated factors such as age, prostate specific antigen (PSA), Gleason score (GS), clinical stage
(T), and use of androgen deprivation therapy (ADT). For patients who received EBRT,
freedom from biochemical failure (FFbF) was evaluated using the Kaplan-Meier method.

Results
Of 379 patients referred for treatment 69.6% had initial PSA (iPSA) >20 ng/ml, and median
iPSA was 39.0 ng/ml. A total of 128 men, representing 33.8% of the overall cohort, were
diagnosed with metastatic disease at time of referral. Among patients with at least 2 years of
follow-up after EBRT treatment (n=52; median follow-up time: 38.9 months), 3- and 5-year
actuarial FFbF was 73.8% and 65.1% respectively. There was significant association between
higher iPSA and GS (8–10 vs. ≤7, p < 0.001), and T stage (T3/4 vs. T1/2, p < 0.001).

Conclusions
This is the largest series reporting on outcomes after prostate cancer treatment in West
Africa. That one-third of patients presented with metastatic disease suggests potential need
for earlier detection to permit curative-intent therapy. Data from this study will aid in the
strategic development of prostate cancer research roadmap in Ghana.
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Background
Prostate cancer is currently the second most often diagnosed cancer and the sixth leading
cause of cancer mortality among males worldwide [1]. Incidence rates vary widely among
different regions with the highest incidences noted among men from the United States and
Europe likely due to utilization of the prostate-specific antigen (PSA) test as a screening tool.
Mortality on the other hand is highest among prostate cancer patients of African descent.
Based on recent estimates, there is a three-fold higher mortality rate for prostate cancer
among patients in African countries as compared to patients in the United States and Europe
[2,3]. This trend has been partly attributed to socio-economic factors and inadequate access to
healthcare [4,5], as well as differences in genetic susceptibility [6-8].
The available medical literature for prostate cancer is primarily from Europe and the United
States. Although the literature does emphasize the outcomes of males of African descent, the
subjects included are those who live in developed countries [9-14], which does not represent
fully the disease characteristics observed in men who reside in African nations [15,16].
Therefore, there is a need to conduct further studies to better understand and describe prostate
cancer in Africa focusing on disease presentation and biochemical failure after currently
available treatments, and to develop a roadmap for clinical research aimed at improving
treatment delivery and outcomes in Africa.

Reports on cancer patterns among Ghanaian men referred to the Korle Bu Teaching Hospital
(KBTH) revealed that prostate cancer comprised 64% of all genitourinary cancers during
1980–1990 [17]. A 10-year retrospective analysis of all cancer deaths at KBTH during 1991–
2000, reported by Wiredu and Armah, demonstrated that prostate cancer was the second
leading cause of cancer-related mortality among their male patients [18]. Recently, Yarney et
al. examined the clinicopathologic features of prostate cancer patients referred to KBTH
during 2003–2007, and showed that the majority of 170 patients referred for radiotherapy at
KBTH presented with initial PSA >20 ng/ml (73%), Gleason score >7 (56%) and were
symptomatic at disease presentation (76%) [19]. This patient profile differs substantially from
those encountered in the United States where median initial PSA at diagnosis is estimated at
6.1 ng/ml and 6.3 ng/ml in Caucasians and Black men respectively [20,21].
Clearly, Ghanaian men present with prostate cancer that is more advanced than observed
routinely in the United States, and the cancer treatment resources differ dramatically. Our
research team plans to develop treatment regimens tailored to the needs of Ghanaian men,
which may differ from guidelines currently utilized in the Unites States and Europe in order
to better address the disease burden and improve mortality rates in Ghana. In this study we
examine early results for definitive radiation therapy for prostate cancer at KBTH, and
develop a research roadmap for improving radiation therapy delivery and outcomes in
Ghanaian men.

Methods
Patient selection
With Institutional Review Board approval from KBTH and Thomas Jefferson University,
patient and treatment data were collected retrospectively from the charts of all patients
referred to the National Center for Radiotherapy and Nuclear Medicine at KBTH for prostate
cancer treatment from January 2003 to December 2009, representing a total of 379 patients.
These patients comprise the cohort for evaluation of patient- and tumor-related factors
presented in the current report (overall cohort). Among these patients, a total of 251 patients
(organ-confined cohort) had non-metastatic disease and were, thus, considered eligible to
receive treatment with curative intent consisting of external beam radiotherapy (EBRT)
(Cobalt-60 unit), brachytherapy, and/or androgen deprivation therapy (ADT). A subset of this
group, the Freedom From biochemical Failure (FFbF) analysis cohort, was identified for
evaluation of outcomes after EBRT, with or without ADT (52 patients). Patients who
received radical prostatectomy were not included in this analysis, since follow up data were
not available. Patients who received radical prostatectomy prior to EBRT or were treated with
brachytherapy were excluded from the FFbF analysis cohort, as were patients with radiologic
or pathologic evidence of metastatic disease prior to treatment. Inclusion criteria included a
biopsy-proven diagnosis of prostate adenocarcinoma, a minimum of 2 years of follow up
data, and at least 2 of the following available: clinical T stage, Gleason score, or initial PSA.
All patients were initially evaluated by a thorough history, physical examination (including
digital rectal examination) followed by routine laboratory studies, bone scan, and serial serum
prostate-specific antigen (PSA) during and after treatment. All patients were staged according
to the 1992 American Joint Committee on Cancer staging system [22]. Patients were further
stratified into low, intermediate and high risk groups according to the recent NCCN
guidelines [23].

Treatment details
External beam radiotherapy
Until 2008, prostate EBRT was performed with 2-dimensional treatment planning using a
conventional fluoroscopic simulator. A 4-field box technique was applied, with parallelopposed pairs of antero-posterior and lateral fields, to deliver up to 68- 70 Gy in 34/35
fractions over 7 weeks. The superior border was placed at the lower sacroiliac joint, with the
inferior border 1 cm above the bottom of the ischial tuberosities. The anterior border on the
lateral film split the pubic symphysis, and posterior border split the S2/S3 vertebrae.
Following the acquisition of a three-dimensional (3D) treatment planning system in 2008,
prostate EBRT involves computed tomography (CT) planning. CT scan images were obtained
in the supine position with 2.5 mm slice cuts and transmitted to a Prowess Panther Treatment
Planning System, version 4.6 (Prowess, Inc., Concord, California). A 3D conformal
radiotherapy technique was used. Clinical target volumes (CTV) included the prostate, with
or without seminal vesicles. For low risk patients, the CTV included the prostate only,
whereas the CTV in intermediate risk patients included the prostate and the inferior 1 cm of
the seminal vesicles. The entire seminal vesicles were included in the CTV for high risk
disease. Typical margins used to generate a planning target volume (PTV) by expanding the
CTV were 1 cm, except posteriorly where the margin was 0.6 cm.
A range of 54-60 Gy was delivered to the initial CTV followed by a second phase, delivering
an additional 10 to 14 Gy to the prostate only. Patients received a cumulative central tumour
dose of 68 to 74 Gy in 34 to 37 daily fractions over 7 to 7-1/2 weeks. A minimum PTV
coverage of 95% coverage was required, with dose inhomogeneity of less than 10% and
maximum point dose was not to exceed 107% of prescription dose. Dose-volume histograms
(DVHs) were obtained for each patient, with a constraint of V60<40% and or V40<60% for the
rectum. Appropriate shielding with customised blocks was employed to decrease the dose to
the rectum and femoral heads. Radiotherapy was delivered using a Cobalt-60 teletherapy
(GWGP 80, National Power Institute of China). Portal imaging was obtained from Cobalt 60
machine prior to and midway through treatment course with correction of any set up errors
identified.

Brachytherapy seed implantation
All patients were seeded using the real-time transrectal ultrasound-guided technique [24].
Iodine-125 sources (Bard Medical Division, Covington, GA, USA) were used in all patients:
low risk patients and intermediate risk patients with PSA < 15 ng/ml were prescribed to
receive dose 160 Gy (pre-TG-43 formalism), intermediate risk patients with PSA > 15 ng/ml
and patients with high risk disease received a partial implant of 110 Gy to the prostate
followed by EBRT of 45 Gy to the pelvis.

Androgen depravation therapy
ADT consisted of orchiectomy or a gonadotropin-releasing hormone agonist (goserelin
acetate) with or without non-steroidal anti-androgen (flutamide or bicalutamide). The use of
ADT was dependent on the risk category of the patient. Short term ADT was offered to
intermediate risk patients (given only concurrently during the 7–8 weeks of radiotherapy).

High risk patients received long term ADT, given for a total of 24 months, beginning 3
months before initiation of radiation [25]. Patients presenting with PSA>100 ng/ml who
completed a negative metastatic work up including bone scintigraphy and CT or magnetic
resonance imaging (MRI) of the pelvis were treated as having localized, high-risk disease
with EBRT + long term ADT. However, those individuals with PSA >100 ng/mL and
symptoms of new onset bone pain were treated with ADT alone as using EBRT was deemed
an exercise in futility due to high likelihood of metastatic disease.
KBTH occasionally receives referrals for consideration of prostate EBRT for patients with
rising PSA levels who previously received orchiectomy for localized disease, and who were
not assessed at initial diagnosis for radical prostatectomy or radiation therapy. These
individuals are evaluated with bone scintigraphy and CT or MRI of the pelvis to determine
whether regional or distant spread of prostate cancer is present. Those without clinical or
radiological evidence of metastases are then considered for EBRT with curative intent.

Follow-up and treatment endpoints
All patients in the FFbF analysis cohort, but not the overall cohort, had a follow up of at least
two years. Patients were seen in follow up every three months for two years, then every six
months for the next three years and once a year subsequently. At each follow up visit,
evaluation included DRE and serial PSA values were determined and recorded. When data
were available, biochemical failure in the analysis cohort was defined according to the
Phoenix definition (PSA nadir + 2 ng/mL). Time to biochemical failure was defined from the
end of EBRT. Freedom From biochemical Failure (FFbF) was used as an endpoint in this
analysis, since it serves as a surrogate for disease-free survival [26]. Patients with follow up
data of less than 24 months after end of EBRT were excluded from FFbF analysis to reduce
the influence of long-term ADT on the observed values in the high-risk patients.

Statistical analysis
Frequency counts and descriptive statistics were used to present information regarding
clinical and pathological features of the cohort. Associations between initial PSA level and
other factors, including Gleason score, clinical T stage and patient age, were tested using
Wilcoxon-Mann–Whitney tests due to the highly skew distribution of PSA levels. For the
FFbF Analysis cohort, 3- and 5-year FFbF rates were evaluated using the Kaplan-Meier
method. Comparisons of FFbF were performed using the log-rank statistic. The threshold for
statistical significance was defined a p-value of <0.05 for all tests. Analyses were performed
using the SAS 9.2 statistical software package (SAS Institute Inc., Cary, NC).

Results
Patient and disease characteristics
The distribution of the clinical characteristics and treatment modalities for the overall cohort
(n=379), the organ-confined cohort (n=251), and the FFbF analysis cohort (n=52) groups are
presented in Tables 1 and 2. The median age at diagnosis among Ghanaian men was 65 years.
Of all patients referred to KBTH for treatment, 69.6% had initial PSA >20 ng/mL with a
median initial PSA of 39.0 ng/mL. As shown in Table 3, there was a significant association
between higher iPSA level and advanced Gleason score (8–10 vs. ≤7, p < 0.001) and clinical

T stage (T3/4 vs. T1/2, p < 0.001). There was no significant association between initial PSA
and age at presentation (<65 vs. 65+) (p= 0.099). A total of 128 men, representing 33.8% of
the overall cohort, were diagnosed with metastatic disease at time of referral and were
excluded from further analysis.
Table 1 Age and tumor characteristics for prostate cancer patients referred for
radiation therapy at Korle Bu Teaching Hospital during 2003-2009
Characteristic Overall Cohort
Organ-Confined Cohort FFbF Analysis Cohort
(n=379)
(n=251)
(n=52)
n (%)
n (%)
n (%)
Age, Y
<60
78(20.6)
55(21.9)
10 (19.2)
60-64
89(23.5)
66 (26.3)
13 (25.0)
65-69
95(25.1)
69 (27.5)
17 (32.7)
70-74
76(20.1)
46 (18.3)
9 (17.3)
>74
41(10.8)
15 (6.0)
3 (5.8)
iPSA ng/ml
0-10.0
50 (13.2)
46 (18.3)
9 (17.3)
10.1-20.0
50 (13.2)
47 (18.7)
10 (19.2)
20.1-50.0
79 (20.8)
61 (24.3)
16 (30.8)
50.1-100.0
70 (18.5)
45 (17.9)
11 (21.2)
100.1-1000.0
73 (19.3)
40 (15.9)
5 (9.6)
>1000
7 (1.9)
2 (0.8)
1 (1.9)
Unknown
50 (13.2)
10 (4.0)
-Gleason Score
≤6
130 (34.3)
114 (45.4)
25 (48.1)
7
102 (26.9)
81 (32.3)
20 (38.5)
8 to 10
71 (18.7)
40 (15.9)
5 (9.6)
Unknown
76 (20.1)
16 (6.4)
2 (3.9)
Clinical T
stage
T1
17 (4.5)
17 (6.8)
-T2
114 (30.1)
114 (45.4)
22 (42.3)
≥T3
77 (20.3)
77 (30.7)
29 (55.8)
Tx
43 (11.4)
43 (17.1)
1 (1.9)
M
128(33.8)
--Risk Group
Low
-20 (8.0)
4 (7.7)
Intermediate
-48 (19.1)
9 (17.3)
High
-166 (66.1)
39 (75.0)
Unknown
-17 (6.8)
--

Table 2 Treatments administered for patients referred for radiation therapy, according
to cohort
Treatment
Overall Cohort
Organ-Confined
FFbF Analysis
Cohort (n=251)
Cohort (n=52)
(n=379)
n (%)
n (%)
n (%)
147 (38.8)
141 (56.2)
52 (100.0)
EBRT
EBRT alone
20 (5.3)
18 (7.2)
4 (7.7)
EBRT + ADT
121 (31.9)
117 (46.6)
48 (92.3)
EBRT + Brachytherapy
2 (0.5)
2 (0.8)
-EBRT+ADT+
4 (1.1)
4 (1.6)
-Brachytherapy
139 (36.7)
60 (23.9)
-ADT alone
LHRH agonist
120 (31.7)
58 (23.1)
-Orchiectomy
38 (10.0)
9 (3.6)
-13 (3.4)
13 (5.2)
-Brachytherapy alone
Table 3 Summary of initial PSA (iPSA) levels by various patient characteristics in the
overall cohort (n = 379)
p-value
Patient Characteristic
iPSA ng/ml (quartiles)
th
th
25 -percentile
Median
75 -percentile
0.099
Age, Y
<65
13.3
32.9
100.0
≥65
19.9
44.8
100.0
< 0.001
Gleason Score
≤7
13.9
27.9
72.8
8 to 10
34.6
68.3
268.2
< 0.001
Clinical T stage
T1 - T2
9.4
19.8
39.0
T3 - T4
22.7
50.4
90.1

Treatment characteristics (Organ-confined cohort)
Among 251 patients with organ-confined disease, eligible for definitive radiation therapy
(RT), 135 patients (53.8%) received EBRT without brachytherapy at the KBTH (Table 2).
Reasons recognized by KBTH clinicians for patients declining EBRT included: the
prohibitive cost of treatment, fear of radiation, and a state of denial based on their perception
of disease originating solely from spiritual causes rather than biologic processes. Patients
treated with EBRT received a median dose of 70 Gy, delivered in 2 Gy daily fractions.
Among the organ-confined cohort, 16 patients received orchiectomy, including 7 patients
who also received EBRT. At least 214 patients (85%) with organ-confined disease presented
with intermediate-to-high risk disease (Table 1). Six patients with low risk prostate cancer
were started on ADT by their referring urologist prior to evaluation at KBTH. Seventeen
patients in the intermediate- and high-risk groups did not receive ADT during EBRT, due to
Gleason score of 5 or less (8 patients) or unaffordable out-of-pocket costs and other
socioeconomic factors (9 patients).

Treatment response (FFbF Analysis cohort)
All members of the FFbF analysis cohort (n=52) received EBRT +/− ADT and had at least 2
years of follow up data after treatment (Table 1). Median ADT time was 24 months. Median
follow up time in this group was 38.9 months. The 3- and 5-year actuarial FFbF was 73.8%
and 65.1% respectively (Figure 1). The 5-year FFbF rates for patients with PSA < 30 ng/mL
and PSA > 30 ng/mL were 67.0% and 63.2%, respectively (log-rank, p= 0.586). Acute
toxicity during treatment included increased fatigue, urinary frequency, nocturia and bowel
frequency, but the rates of these events could not be assessed in the available records. None
of the patients on treatment were known to require any surgical intervention or inpatient
hospitalization from treatment related causes.
Figure 1 Kaplan-Meier plot of survival curve of Freedom-From Biochemical Failure
(FFbF) for the Analysis Cohort (n=52) of patients who received external beam radiation
therapy at Korle Bu Teaching Hospital in Ghana and who were followed for at least 2
years after treatment. Dotted lines represent 95% confidence interval.

Discussion
Over the last few decades, there has been a noted increase in the burden of chronic diseases,
especially cancer, in Africa [27]. Simultaneously, trends in other factors such as extensive
urbanization and lifestyle changes, including smoking, alcohol consumption, and the
adaptation of a Western diet, have been linked to an increased risk of cancer [28]. Prostate
cancer contributes significantly to these patterns. A recent report on the cancer mortality
pattern in Ghana following a 10-year review of autopsies and hospital mortality revealed that
prostate cancer was the second leading cause of death from cancer among men in Ghana [18].
Furthermore, the incidence of prostate cancer is on the rise in Ghana, due in part to the fact
that the life expectancy of working men has increase over the last decade and better health
care facilities have improved detection of disease [19].
The current study describes characteristics of prostate cancer patients referred to KBTH in
Ghana and provides insight into early clinical outcomes for the treatment of advanced disease
in this population. These data are significant, in terms of defining priorities for cancer care in
West Africa, since the majority of the prostate cancer literature originates from the United
States and Western Europe and there is an increasing awareness that results obtained from
one ethnicity may not necessarily apply to individuals from a different ethnic origin. Over the
last two decades, data have emerged from hospital-based cancer registries in a few African
countries that provide valuable information. Data from several articles on prostate cancer
from 1981 to 2005 indicate an increased prostate cancer risk and mortality among Nigerian
men [29-31]. Another study among Senegalese men with prostate cancer revealed worse
tumor stage and median PSA when compared with that of African American men [20]. Data
from the current study suggest similar findings in our cohort of Ghanaian men. Although this
study was done in the largest cancer center in Ghana generalizing this data to all Ghanaian
men with prostate cancer must be done with caution. In this section, we will apply these data
toward consideration of research priorities aimed at improving prostate cancer diagnosis and
treatment in Ghana.

PSA screening
In our study population of Ghanaian men with prostate cancer, >90% of patients with
available data presented with intermediate- or high-risk disease, >95% with clinically T2 or
greater disease, and 70% with PSA >20 ng/ml. In contrast, in the US population, 40-60% of
prostate cancer patients present with clinically inapparent disease, mostly diagnosed as T1c
upon trans-rectal ultrasound guided (TRUS) biopsy [32,33]. Furthermore, less than 15% of
prostate cancer patients in the US population present with PSA > 20 ng/ml [34]. This may be
attributed to PSA screening efforts and more frequent TRUS biopsies of prostate in
developed countries. Currently, routine yearly PSA screening is a source of controversy in
the United States [35], but this approach is not feasible in Ghana where the costs would be
prohibitive. Moreover, the effect of PSA screening on prostate cancer mortality in the United
States and Europe has been inconclusive. Data from the Prostate Lung Colorectal and
Ovarian (PLCO) trial did not show a survival benefit from screening, however the European
Randomized Study of Prostate Cancer (ERSPC) trial demonstrated a 31% reduction in the
risk of death from prostate cancer in men that had PSA screening [36].
There are major concerns that PSA screening leads to over-diagnosis and overtreatment of
indolent prostate cancer in men which if left untreated would have little or no impact on life
expectancy [37]. However, in men of African descent who may demonstrate more aggressive
disease, the lack of screening could result in an increased number of patients presenting with
high risk disease, which would adversely impact prostate cancer mortality rates. This is
exemplified in the analysis of our patient cohort showing a strong correlation between PSA
levels at diagnosis and advanced clinical T stage as well as Gleason score. Based on trends of
prostate cancer mortality in Ghana and the vast majority of patients presenting with high risk
disease, it would be advantageous to develop a healthcare policy that will allow for PSA
screening along with DRE in a selected cohort of men. Although annual PSA screening
would likely exceed financial constraints in Ghana, it may be worthwhile to consider a
program that includes less frequent screening. Determining the appropriate initial age for
screening and the appropriate time interval for PSA screening in Ghana is beyond the scope
of this study, but future studies should address these considerations.

Challenges to treatment delivery
Out of 251 patients eligible for definitive radiation treatment with curative intent only 141
patients (56.2%) actually received EBRT. A number of factors acting as barriers to treatment
delivery include the use of alternative medicines and traditional healing methods coupled
with inadequate health education, which often delays correct diagnosis and initiation of
treatment. Furthermore, taboos, stigmas, and false beliefs that cancer is a “curse” often lead
to delayed diagnosis and non-adherence to treatment. Other barriers specific to radiation
treatment delivery among Ghanaian men included fear of radiation, inflated perception of the
cost of treatment, difficulty with access to transportation to and from daily treatments, and
loss of income due to absence or inability to work.
Ghana has a population of 24 million serviced by only two megavoltage machines in two
radiation treatment centers 250 kilometers (180 miles) apart. The lack of accessibility to
treatment centers as well as time loss and costs incurred by patient transportation presents a
huge barrier for compliance to daily treatments. Furthermore, the national health insurance
re-imbursements payment rate to the health care facilities is very low, which in turn renders
the out of pocket cost per treatment course per patient enormously expensive for the average

working-class Ghanaian man. Currently, shorter course (“hypofractionated”) treatment
schedules are being explored for prostate cancer, in an effort to improve patient convenience,
reduce costs, and to take advantage of unique radiobiological characteristics of prostate
cancer that make large fractions potentially more effective [38]. The adaptation of a
hypofractionated schedule for treatment in Ghana would offer a profound advantage in not
only decreasing healthcare delivery costs but also improve access to treatment by reducing
transportation time and expense for patients during radiation therapy. This represents a
potential for implementing tailored prostate cancer treatment schemes for developing
countries, an important focus for future studies. To this end, we propose to develop and
conduct clinical trials of shorter course radiation therapy schedules tailored to the needs of
Ghanaian prostate cancer patients.

Treatment outcomes
To date, the data presented in this article provides the only source of published information
on outcomes for prostate cancer treatment in the West African region. Our results showed
that the 3- and 5-year FFbF for Ghanaian men with mostly intermediate to high risk prostate
cancer receiving EBRT +/− ADT was 73.8% and 65.1% respectively. In light of differences
in patient disease characteristics at diagnosis and older treatment techniques one must
consider whether to evaluate these outcomes with respect to the latest published data using
dose escalation as reported by Zietman et al. [21] that demonstrated a 80-90% biochemical
control as opposed to older experiences from randomized trials such as RTOG 9202 [39] and
EORTC 22863 [40] showing biochemical failure rates as high as 50-76% for patients with
advanced tumors. A major drawback to this retrospective study is the limited ability to assess
important end points such as impact of treatment on cause-specific survival and distant
metastases free survival due to a median follow up data of only 3 years. Nevertheless, there is
valuable information presented in this article that will aid in the strategic development of a
roadmap for prostate cancer research in Ghana, with a focus on improving therapeutic
approach as well as fostering a prudent allocation of scarce resources.

Future research needs
Results presented in this study have demonstrated that the majority of Ghanaian men
diagnosed with prostate cancer present with very advanced stage disease. Current treatment
recommendations for advanced stage prostate disease are based on clinical trials that include
conventionally-fractionated radiation therapy and long-term ADT [39-41]. However, the
availability of modern treatment technologies and the more recent interest in
hypofractionation for prostate cancer offer an opportunity to develop studies aimed at
improving the treatment and outcomes for Ghanaian patients with advanced stage prostate
disease. The Ghanaian prostate cancer patient population is in need of clinical trials that seek
to develop novel, shorter course treatment regimens for locally-advanced prostate cancer. We
have established collaboration between two institutions with the hope of improving prostate
cancer treatment in Ghana and plan to develop clinical trials that can be conducted in tandem
between our two institutions. Our group encourages approaching the design of clinical trials
in a way that includes perspective of the public health burden of prostate cancer in Ghana and
the specific barriers to care. We hope to achieve progress by involving stakeholders in a
coordinated fashion to develop tailored radiation treatment techniques that are cost-effective
and well-suited for the needs of Ghanaian men.

Conclusion
We have described presentation and early clinical outcomes for a cohort of patients who
received prostate cancer treatment at KBTH in Ghana. Based on these results, our group has
proposed a plan for future research aimed at identifying an appropriate role for PSA
screening in this population, developing radiation therapy treatment schedules that better
fulfill the needs of Ghanaian prostate cancer patients, and contributing to understanding
genetic factors associated with prostate cancer risk and treatment response.
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